News

Video

Community Is ‘One of the Biggest Assets’ for Patients With MPNs

Author(s):

An expert explained the benefits of patients with myeloproliferative neoplasms finding a community of people with similar diagnoses.

Patients with myeloproliferative neoplasms (MPNs) can find immense benefit from joining a community of people with a similar diagnosis, according to Nichole Ard, senior clinical studies coordinator at The University of Texas MD Anderson Cancer Center in Houston.

MPNs are a group of rare blood disorders that affect the way that the bone marrow makes blood. MPN groups help patients connect, review resources and become more educated on their disease, according to Ard, who was also honored at CURE®’s 11th annual MPN Heroes® recognition event.

READ MORE:LeVar Burton Gives ‘Voice and Visibility’ to Patients with MPNs Through Storytelling and Advocacy

“I have patients that come in and they already know what I'm going to say half the time because they've talked to somebody else who's told them their story,” Ard said in an interview with CURE® ahead of the event.

Transcript

With my work, I've found that MPN patients find a community. There is a large community of patients that have gotten together, and they talk, and they review resources, and they tell their stories to each other, and I feel like that is probably one of the biggest assets for that community is that they are able to do those things.

I have patients that come in and they already know what I'm going to say half the time because they've talked to somebody else who's told them their story. And so I think that's a big part of any cancer is finding community, finding somebody who can relate with you in, in what you're going through. And I've, I've just found that that's been super helpful for my patients.


For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Dr. Michael Bogenschutz
Photo credit: Max Mumby/Indigo via Getty Images
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine, in the Department of Medicine, at Beth Israel Deaconess Medical Center in Boston.
Dr. Stephanie Alice Baker
Dr. Aditya Bardia is a professor in the Department of Medicine, Division of Hematology/Oncology, director of Translational Research Integration, and a member Signal Transduction and Therapeutics, at University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.
Dr. Laura Dawson, a professor and chair of the department of Radiation Oncology at the University of Toronto, and a practicing radiation oncologist in the Radiation Medicine Program at Princess Margaret Cancer Center, University Health Network in Toronto.
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Michael Bogenschutz, director of the NYU Langone Center for Psychedelic Medicine in New York,
Related Content